Furthermore, capivasertib, an AKT inhibitor, has demonstrated efficacy in HR+/HER2− BC patients harboring PIK3CA, AKT1, or PTEN alterations following disease progression on standard adjuvant therapies (19). This evidence concerns the gene PIK3CA and breast cancer.